Amsterdam, The Netherlands, 7 March 2014. LSP (Life Sciences Partners), a leading European life sciences investor, announces the final closing of its Health Economics Fund at €112 million ($155 mln), exceeding its target of €100 mln.
The fund (LSP HEF) invests in healthcare companies commercializing products in the areas of medical technology, diagnostics and eHealth. The unique angle of LSP HEF is that it invests only in companies with products or technologies that improve the quality of healthcare and reduce its cost at the same time. Such products are of high relevance to patients, care providers and, given the global rise in healthcare costs, to society at large. LSP HEF has privileged access to a database comprised of deep and broad information on the cost of current diagnosis and treatment of diseases. This allows the fund to make a comparative analysis of costs between new and existing products based on real life data.
LSP HEF will invest in Europe and North America, focusing on later stage private companies with products on the market or close to market introduction. The fund made its first investment in IlluminOss Medical, a US company commercializing an innovative, minimally invasive and cost saving approach to orthopedic implants for the treatment of bone fractures.
“We are delighted to have Dutch, German and French health insurance companies as LPs, next to a number of top quality family offices and asset managers” says René Kuijten, general partner LSP. Rudy Dekeyser, managing partner LSP HEF, adds “the concept of sustainable health care is very attractive to investors who expect a socio-economic return next to a financial return. In parallel with the fundraising we have built a rich portfolio of interesting investment dossiers and expect to make several more investments in the coming months.”
Note for Editors
LSP (Life Sciences Partners) is one of Europe’s leading investors in the health care sector. Over more than 25 years, LSP has built elaborate expertise in establishing and growing health care companies with a positive impact on society. In partnership with inventors and entrepreneurs LSP contributes to the translation of breakthrough concepts into products that benefit patients. LSP connects LPs to inventors with a dual goal: generating an interesting financial return and contributing to the quality of life. LSP has offices in Amsterdam, Munich and Boston and has raised over €700 mln ($960 mln) in funds. For more information please visit the new LSP website: www.lspvc.com
Dr. René Kuijten, General Partner LSP, email@example.com ">firstname.lastname@example.org
Dr. Rudy Dekeyser, Managing Partner LSP-HEF, email@example.com ">firstname.lastname@example.org
LSP: +31 (0)20 664 55 00 and www.lspvc.com« back to overview